Navigation Links
Quark Pharmaceuticals Presented At ARVO Data Showing That PF-04523655 Enters Retinal Cells And Elicits Its Pharmacologic Effect Via Target Gene Knock-Down Without Activating TLR3
Date:5/11/2009

FREMONT, Calif., May 11 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that Elena Feinstein, M.D., Ph.D., Chief Scientific Officer, presented a study titled, "PF-04523655 (REDD14NP), an siRNA Compound Targeting RTP801, Penetrates Retinal Cells Producing Target Gene Knockdown and Avoiding TLR3 Activation," at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, taking place from May 3-7, 2009, in Fort Lauderdale, Florida. PF-04523655 is currently being studied by partners Pfizer and Quark in patients with diabetic macular edema (DME) and age-related macular degeneration (AMD).

The study presented at ARVO was performed in collaboration with Dr. Jayakrishna Ambati at the Department of Ophthalmology and Visual Sciences, University of Kentucky College of Medicine, Lexington, KY. The objective of the study was to determine whether PF-04523655, a synthetic chemically modified 19-bp siRNA, enters cells in the retina leading to downregulation of its target gene while avoiding activation of Toll Like Receptor 3 (TLR3). Previous studies from Dr. Ambati's laboratory have shown that unmodified 21-mer siRNA molecules exhibit antiangiogenic effects by inadvertently activating TLR3 rather than down-regulating expression of their target genes. Results obtained in vivo and in vitro indicated that PF-04523655 does enter cells in the retina and elicits its pharmacologic effect via target gene knock-down without activating TLR3.

Daniel Zurr, Ph.D., President and Chief Executive Officer, said, "We believe that the results presented at ARVO continue to substantiate our leadership in siRNA therapeutics, in particular Quark's ability to develop highly specific siRNA products and advance them through the clinic toward commercialization. Quark's ability to establish col
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference
2. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
3. Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008
4. Quark Pharmaceuticals to Present at American Society for Pharmacology and Experimental Therapeutics Annual Meeting
5. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
11. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar will ... and clinical safety assessment in biosimilars. , Regulatory frameworks ... biosimilar drug development, however the complex nature of biopharmaceuticals ... safety and efficacy extremely challenging. Based on the specific ...
(Date:1/15/2014)... 2014 DTS Language Services, Inc . ... Portal for Life Science organizations who need document translations. ... matter of their documents in advance with a selection of ... of translations, often a critical factor in clinical and scientific ...
(Date:1/14/2014)... 14, 2014 Date: Friday, April 11, 2014 ... Country Club, 1360 Almshouse Road, Warrington, Pa. , ... solely dedicated to finding a cure for hepatitis B and ... host its annual Crystal Ball on Friday, April 11 at ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, ... is an emerging biomedical company acquiring, developing, manufacturing, and ... , Free report download: http://equitiesiq.com/reports/alliqua/ , In ... team and Board, which launched the company’s new strategy ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... to provide high coverage and megabase capacity for ... Germany, March 16 febit today ... capture technology HybSelect. In several biomedical studies of ... demonstrated superb enrichment factors and deep sequencing coverage ...
... Outstanding Indevus Shares Have Been Accepted for PurchaseCHADDS ... ENDP ) announced today that, as ... March 13, 2009, approximately 71,008,964 shares (including shares ... tendered and accepted for purchase in the tender ...
... - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ... reovirus (REOLYSIN(R)) are available on the American Association for ... on the Oncolytics website at www.oncolyticsbiotech.com . The ... AACR Annual Meeting in Denver, Colorado, April 18-22, 2009. ...
Cached Biology Technology:Automated Sequence Capture for Next-Generation Sequencing Paves the Way for Personalized Medicine 2Automated Sequence Capture for Next-Generation Sequencing Paves the Way for Personalized Medicine 3Endo Pharmaceuticals Extends Subsequent Offering Period for Indevus Shares Until 5:00 pm EDT on Wednesday, March 18, 2009 2Endo Pharmaceuticals Extends Subsequent Offering Period for Indevus Shares Until 5:00 pm EDT on Wednesday, March 18, 2009 3Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting 2Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting 3
(Date:4/17/2014)... need to produce hydrogen sulfide in order to properly ... study from the Center for Craniofacial Molecular Biology at ... Professor Songtao Shi, principal investigator on the project, said ... governs the flow of calcium ions. The essential ions ... osteogenesis, or the creation of new bone tissue, and ...
(Date:4/17/2014)... White House honored Clemson professor Rajendra Singh Thursday ... to promote and expand solar deployment in the ... D. Houser Banks Professor of Electrical and Computer ... Nanoelectronics, is considered a local hero leading the ... economic opportunity in solar power and driving policy ...
(Date:4/17/2014)... that devastate honeybees in Europe, Asia and the United ... appear to be impacting native honeybee populations at this ... invasive pests include including Nosema microsporidia and ... to be resilient to these invasive pests, which suggests ... in Europe, Asia and the United States currently are ...
Breaking Biology News(10 mins):White House honors Clemson professor as 'Champion of Change' for solar deployment 2East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3
... researchers has completed a first draft of the cassava (Manihot ... accelerating the pace of research on this subsistence crop and ... around the world. Cassava is a root crop that ... million people each day. Although it has many properties that ...
... Scientists and industry leaders from around the world will ... Molecular Targets and Cancer Therapeutics International Conference, which will ... "Cancer is a complex disease and to ... the activity that takes place at the molecular level," ...
... open for the Society of Interventional Radiology,s "Image-guided ... the latest updates on percutaneous and transcatheter treatment ... tumor ablation. SIR is a national organization of ... improving public health through pioneering advances in image-guided ...
Cached Biology News:Researchers complete draft genome sequence for cassava 2Researchers complete draft genome sequence for cassava 3Researchers complete draft genome sequence for cassava 4Society of Interventional Radiology hosts oncology therapies Webinar, offers resources 2
Request Info...
Guinea Pig Complement...
Collected from 8-12 week-old New Zealand or Californian rabbits....
Enables rapid purification of double-stranded DNA fragments = 200 bp, including, for example, PCR reaction products, DNA fragments obtained in restriction enzyme digests, or double-stranded cDNA...
Biology Products: